Metopimazine mesylate is under clinical development by Neurogastrx and currently in Phase II for Nausea. According to GlobalData, Phase II drugs for Nausea have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Metopimazine mesylate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Metopimazine mesylate overview
Metopimazine mesylate (NG-101) is under development for the treatment of diabetic or idiopathic gastroparesis, nausea and vomiting associated with glucagon-like peptide 1 (GLP-1) agonists. It is administered through oral route as capsule formulation. The drug candidate targets dopamine D2/D3 receptor. Dopamine receptors are members of the rhodopsin-like G-protein coupled receptor family.
Neurogastrx overview
Neurogastrx, a biopharmaceutical company that developing therapies for gastrointestinal disorders. The company is headquartered in United States.
For a complete picture of Metopimazine mesylate’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
